ArticlePloS one2025
Molecular genetic portrait of virulence and ciprofloxacin resistance genes in clinical Pseudomonas aeruginosa Isolates from Khartoum, Sudan.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa remains a major cause of hospital- and community-acquired infections, with increasing ciprofloxacin resistance driven by mutations in quinolone resistance-determining regions (QRDRs) and plasmid-mediated mechanisms. This study aimed to determine the prevalence of key virulence genes (oprI, toxA, lasB, nan1) and ciprofloxacin resistance determinants (gyrA, parC, qnrA, qnrB, qnrS) in clinical isolates from Khartoum State, Sudan, and to explore associations with demographic and clinical variables.
methodsThis cross-sectional study, which was conducted from January to April 2023, included eighty-six clinical isolates of P.aeruginosa that were collected from various hospitals in Khartoum State. The isolates were reidentified via standard microbiological techniques, and DNA was extracted via the boiling method. Multiplex polymerase chain reaction was utilized to detect the presence of virulence and ciprofloxacin resistance genes. Data analysis was performed via IBM SPSS software (version 20).
resultsAll the isolates carried one or more virulence genes, with oprI being the most prevalent (88.4%), followed by lasB (80.2%), toxA (57%), and nan1 (6.98%). Among the isolates, 30 (34.9%) were resistant to ciprofloxacin, whereas 56 (65.1%) were susceptible. All resistant isolates carried at least one of the resistance genes studied. The parC gene was the most prevalent (40.7%), followed by gyrA (20.9%) and qnrS (19.8%). qnrA and qnrB each had a prevalence of 17.4%. This investigation revealed the coexistence of the gyrA and parC genes in seven isolates (23.3%), and we also reported that the qnrA, qnrB, and qnrS genes coexisted in 11 (36.7%) of the ciprofloxacin resistant P. aeruginosa isolates. A significant association was detected between ciprofloxacin resistance and the presence of the gyrA, qnrS, qnrA, and qnrB genes (p < 0.001) but not the parC gene (p = 0.6). There was no significant association between ciprofloxacin resistance genes and virulence genes (p > 0.05).
conclusionsThe prudent use of ciprofloxacin is vital in managing P.aeruginosa infections amid rising resistance. Detection of gyrA and parC in susceptible isolates signals potential for future resistance through future mutations, highlighting the need for ongoing monitoring. The coexistence of resistance and virulence genes highlights the pathogen's combined threat. These findings reinforce the public health importance of continuous molecular surveillance and genetic profiling, not only to guide effective treatment but also to inform targeted infection control strategies and antimicrobial stewardship programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.